|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125.00 GBX | -0.79% |
|
+4.17% | - |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| 07-13 | PureTech Health: Celea Therapeutics Kicks Off Late-stage Trial for Idiopathic Pulmonary Fibrosis Drug | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 127.2 | 140.2 | 141.2 |
| Spread/Res. | -1.73% | -10.84% | -11.47% |
| Spread/Supp. | +5.75% | +15.74% | +13.64% |
| Support | 118.2 | 108 | 110 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- PRTC Stock
- Charts PureTech Health plc
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
